Rise and shine, everyone, another busy day is on the way. Yes, this may be holiday time for many folks, but the world continues to spin for the rest of us. The truth hurts, yes? So we can all cope together by quaffing cups of stimulation. The neurons can always use a little help, after all. Our choice for this task is hot buttered rum, by the way. What is your preference? While you decide, you can peruse the tidbits we have assembled. Hope your day goes well and, as always, do keep in touch. …

An Oklahoma judge ordered Johnson & Johnson (JNJ) to pay $572 million for contributing to the state’s opioid-addiction crisis, a verdict that could signal further findings of liability for drug companies as similar cases wind through courts across the country, The Wall Street Journal writes. Oklahoma state court judge Thad Balkman said the state proved J&J launched a misleading marketing campaign to convince the public that opioids posed little addiction risk and were appropriate to treat a range of chronic pain.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy